Genenta Science (Nasdaq: GNTA) Company Profile, Contacts & Intelligence

Genenta Science (Nasdaq: GNTA) Overview

Genenta (Nasdaq: GNTA) is a clinical stage immuno-oncology company developing a proprietary hematopoietic stem cells therapy for the treatment of a variety of solid tumor cancers. Genenta's first in class product candidate is Temferon™, which is designed to allow the expression of immune-therapeutic payloads within the tumor microenvironment by bone marrow derived myeloid cells and enable a durable and targeted response. Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme patients with an unmethylated MGMT gene promoter, which suggests the potential reprogramming of the tumor microenvironment and inhibiting of myeloid induced tolerance, while allowing the induction of T cell responses, potentially breaking immune tolerance. Genenta has initiated in Q4 2024 a Phase 1/2a metastatic Renal Cell Carcinoma study that will also include combination with immune checkpoint inhibitors. Our treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics.

Headquarters

IT

Website

genenta.com

Industry

Biotechnology Research

Founded

2014

Stock Symbol

GNTA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology)

Company Email

Available in AeroLeads

Genenta Science (Nasdaq: GNTA) Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

Genenta Science (Nasdaq: GNTA) People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Genenta Science (Nasdaq: GNTA) Workforce Composition

Seniority breakdown across 6 visible profiles.

Compare Similar Companies to Genenta Science (Nasdaq: GNTA)

Explore companies in related markets and compare their industry and employee estimates.